Is AGNC Investment's Huge Yield as Attractive as It Seems?
AGNC Investment has a lofty 16% dividend yield.
The company went public at $20 per share but now trades for around $9.
The dividend has declined from a quarterly peak of $1.50 to a current level of $0.36.
10 stocks we like better than AGNC Investment Corp. ›
AGNC Investment (NASDAQ: AGNC) stands out for one very big reason: Its huge 16% dividend yield. That's dramatically higher than the 1.3% yield of the S&P 500 index (SNPINDEX: ^GSPC) and the 4.1% yield of the average real estate investment trust (REIT). Is that lofty yield as attractive as it looks? The answer is a little complicated.
Putting aside AGNC Investment's business (it is a mortgage REIT, or mREIT) for a second, the stock shows up prominently on just about all lists of high-yield stocks. That's notable because the way an investor analyzes dividend stocks is vastly different from the way a growth stock would be analyzed, as just one example. So the first big question to answer with AGNC Investment is "How good a dividend stock is this REIT?"
The answer for most investors will likely be "Not very good." As the chart above highlights, the dividend rose sharply at its initial public offering (IPO), which is normal for a dividend-paying company, and then started a long-term decline. From the peak to the current level, the dividend has fallen from $1.50 per share per quarter to just $0.36.
The share price followed a similar path, rising to a peak of over $36 as the dividend increased only to start a long decline to about $9 as the dividend was steadily reduced.
Most dividend investors are likely trying to find a stock that can provide them with reliable income to pay for living expenses in retirement. AGNC Investment has not provided that. In fact, if you used the dividends to pay for living expenses, you would have ended up with less income and less capital. That's a really bad outcome.
What's interesting about AGNC is that it doesn't hide the fact that it isn't really a dividend stock. On its home page, it effectively touts total return as its big goal, but with a "substantial yield component." Total return assumes that dividends are reinvested.
The mREIT's first quarter highlights this dynamic in action. The company noted that it had a "2.4% economic return on tangible common equity for the quarter." That was "comprised of $0.36 dividends per common share and $(0.16) decrease in tangible net book value per common share."
Essentially, it paid out more in dividends than it lost in tangible net book value. Tangible net book value is different from share price; it is more like a net asset value for a mutual fund. But this dynamic is an important one for investors to understand.
Looking over the long term, the stock price at the IPO was $20. In other words, as of today the stock is worth $11 less than at the time of the share offering. But the REIT has paid out $49.24 per share in dividends. The net result is $38 or so more in dividends than was lost in the share price decline. That's why AGNC's total return is positive since its IPO, despite the falling dividend and share price.
This is a nuanced view of the stock. In fact, a dividend investor could argue that even spending the dividends has resulted in a net positive outcome based on the full picture.
It's just that most dividend investors don't think this way. And since there are plenty of dividend stocks that have attractive yields, growing dividends, and stock prices that have largely risen over time, there's no reason for them to start looking at a more complex situation like AGNC.
The company isn't a bad mortgage REIT. In fact, it does a pretty good job of providing its shareholders with total return via an investment in mortgage securities. And dividends play a very important role in that story, whether they are reinvested or not.
Still, this is probably not the type of investment that dividend investors will want in their portfolio. The lofty yield simply isn't as attractive as it seems, even though the dividend story here may not be as bad as it seems, either.
Before you buy stock in AGNC Investment Corp., consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AGNC Investment Corp. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!*
Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 2, 2025
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Is AGNC Investment's Huge Yield as Attractive as It Seems? was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
17 minutes ago
- Business Insider
iOThree receives Nasdaq notification regarding minimum bid price deficiency
iOThree (IOTR) Limited announced that it has received a written notification from the Nasdaq Stock Market LLC on June 3, 2025, indicating that the Company was not in compliance with the $1.00 closing bid price requirement for the last 30 consecutive business days from April 21, 2025 to June 2, 2025 under the Nasdaq Listing Rule 5550(a)(2). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Nasdaq notification has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker 'IOTR'. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until December 1, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ordinary shares must be at least $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. Confident Investing Starts Here:


Business Insider
38 minutes ago
- Business Insider
Playa Hotels receives Mexican antitrust approval of pending sale to Hyatt
Playa Hotels & Resorts (PLYA) announced that all required approvals relating to anti-competition filings under Ley Federal de Competencia Economica in Mexico in connection with the Company's pending sale to HI Holdings Playa B.V., an indirect wholly owned subsidiary of Hyatt Hotels Corporation (H), have been granted. Antitrust approval in Mexico was the final regulatory approval required to complete the transaction. Completion of the tender offer remains subject to the conditions described in the tender offer statement on Schedule TO, including the satisfaction of the minimum tender condition by Playa shareholders. Hyatt's tender offer to acquire all of the outstanding ordinary shares of Playa for $13.50 per share in cash, less any applicable withholding taxes and without interest, is scheduled to expire at 5:00 p.m., New York City time, on June 9, 2025. The offer is being made pursuant to the previously announced purchase agreement, dated February 9, 2025, among Hyatt, Buyer and Playa. Assuming the minimum tender and other offer conditions are satisfied, the tendered shares are expected to be accepted for payment on or about June 11, 2025. Pursuant to the terms of the Purchase Agreement, if the minimum tender condition in the Hyatt tender offer is satisfied, along with certain other closing conditions expected to be satisfied at expiration, then on June 10, 2025, Hyatt will commence a subsequent offering period for the tender offer for any Playa ordinary shares not already tendered, which will expire at 11:59 p.m., New York City time, on June 16, 2025. Following this subsequent offering period and the related transactions required by the Purchase Agreement, Playa expects that Hyatt will own all ordinary shares of Playa on or about June 17, 2025. Playa also announced today that it has submitted written notice to Nasdaq of its intention to voluntarily delist its ordinary shares from Nasdaq. The voluntary delisting is subject to and conditioned upon the expiration of the Hyatt tender offer as described above and the acquisition by Hyatt of all ordinary shares validly tendered and not properly withdrawn in accordance with the Purchase Agreement. If such conditions are satisfied, then on or about June 16, 2025, Playa intends to file with the U.S. Securities and Exchange Commission a notification of removal from listing of its ordinary shares on Nasdaq. Completion of the tender offer remains subject to the conditions described in the tender offer statement on Schedule TO filed by Hyatt and Buyer with the SEC on February 24, 2025.
Yahoo
an hour ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio